why choose us

First received: December 09, 2022

Clinical Trial: Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

Study Status: Completed

Recruit Status: RECRUITING

Condition: Bile Duct Cancer

Study Type: INTERVENTIONAL


Official Title: A Single Arm Phase 2 Study of Y-90 SIRT in Combination With Durvalumab (MEDI 4736) and Gemcitabine/Cisplatin in Locally Advanced, Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Brief Summary: This trial is designed to study a combination of interventions (chemotherapy, immunotherapy, and radiation) as a potential new treatment for bile duct cancer that cannot be removed with surgery.The specific names of the interventions that will be used are:Y-90 (a type of radiation microsphere bead)Durvalumab (a type of immunotherapy)Gemcitabine (a type of chemotherapy)Cisplatin (a type of chemotherapy)

Read more